This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/moderna-covid-vaccine-sales-stock-earnings-miss-d244f129
- Order Reprints
- Print Article
Moderna stock fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations.
The biotech company (ticker: MRNA) reported earnings per share of $3.61 in the fourth quarter on revenue of $5.1 billion.
